[logo] HealthTree Foundation
search person

Clinical Trial: Which is Better Induction Therapy, RVD or CRD? Study Open for Newly Diagnosed Myeloma Patients

Posted: Oct 13, 2016
Clinical Trial: Which is Better Induction Therapy, RVD or CRD? Study Open for Newly Diagnosed Myeloma Patients image

Which up-front therapy combination is best for newly diagnosed multiple myeloma patients? This study is comparing two proteasome inhibitors which are combined with lenalidomide (an iMiD) and dexamethasone (a steroid.) The class of proteasome inhibitors are are critical staple for myeloma therapy, but is one better than another? We are hopeful that this clinical trial can give insight into which proteasome inhibitor is best for which type of patient, age, pre-existing conditions and myeloma genetics. This trial is open in many locations on the East coast including local cancer centers, and will include over 700 newly diagnosed multiple myeloma patients. To learn more about this study or to join, click here: RVD or CRD Clinical Trial for Newly Diagnosed Patients  

Which up-front therapy combination is best for newly diagnosed multiple myeloma patients? This study is comparing two proteasome inhibitors which are combined with lenalidomide (an iMiD) and dexamethasone (a steroid.) The class of proteasome inhibitors are are critical staple for myeloma therapy, but is one better than another? We are hopeful that this clinical trial can give insight into which proteasome inhibitor is best for which type of patient, age, pre-existing conditions and myeloma genetics. This trial is open in many locations on the East coast including local cancer centers, and will include over 700 newly diagnosed multiple myeloma patients. To learn more about this study or to join, click here: RVD or CRD Clinical Trial for Newly Diagnosed Patients  

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

Thanks to our sponsors:
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.